These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33189118)

  • 1. Diagnosis and Management of Problematic Severe Asthma.
    Scotney E; Saglani S
    Acta Med Acad; 2020 Aug; 49(2):117-129. PubMed ID: 33189118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. This Child's Asthma Appears to Be Severe: But Where Actually Is the Severe Problem?
    Bush A
    Acta Med Acad; 2020 Aug; 49(2):103-116. PubMed ID: 33189117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe asthma in children: therapeutic considerations.
    Selby L; Saglani S
    Curr Opin Allergy Clin Immunol; 2019 Apr; 19(2):132-140. PubMed ID: 30720474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exhaled nitric oxide in children with asthma receiving Xolair (omalizumab), a monoclonal anti-immunoglobulin E antibody.
    Silkoff PE; Romero FA; Gupta N; Townley RG; Milgrom H
    Pediatrics; 2004 Apr; 113(4):e308-12. PubMed ID: 15060258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does allergy explain why some children have severe asthma?
    Bonner K; Roberts G
    Clin Exp Allergy; 2018 Dec; 48(12):1594-1605. PubMed ID: 30019503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of omalizumab on small airway inflammation as measured by exhaled nitric oxide in moderate-to-severe asthmatic patients.
    Pasha MA; Jourd'heuil D; Jourd'heuil F; Mahon L; Romero F; Feustel PJ; Evans M; Smith T; Mitchell J; Gendapodi P; Demeyere-Coursey KC; Townley RG
    Allergy Asthma Proc; 2014; 35(3):241-9. PubMed ID: 24801467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach.
    Bossley CJ; Fleming L; Ullmann N; Gupta A; Adams A; Nagakumar P; Bush A; Saglani S
    J Allergy Clin Immunol; 2016 Aug; 138(2):413-420.e6. PubMed ID: 27061250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An approach to the management of children with problematic severe asthma.
    Fainardi V; Saglani S
    Acta Biomed; 2020 Sep; 91(3):e2020055. PubMed ID: 32921752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can inflammatory markers in induced sputum be used to detect phenotypes and endotypes of pediatric severe therapy-resistant asthma?
    Eller MCN; Vergani KP; Saraiva-Romanholo BM; Antonangelo L; Leone C; Rodrigues JC
    Pediatr Pulmonol; 2018 Sep; 53(9):1208-1217. PubMed ID: 29870159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and Management of Severe Asthma.
    Chung KF
    Semin Respir Crit Care Med; 2018 Feb; 39(1):91-99. PubMed ID: 29427989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
    Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
    J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching from omalizumab to mepolizumab: real-life experience from Southern Italy.
    Carpagnano GE; Pelaia C; D'Amato M; Crimi N; Scichilone N; Scioscia G; Resta O; Calabrese C; Pelaia G; Quarato CMI; Foschino Barbaro MP
    Ther Adv Respir Dis; 2020; 14():1753466620929231. PubMed ID: 32482128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
    Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
    Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Getting the basics right resolves most cases of uncontrolled and problematic asthma.
    de Groot EP; Kreggemeijer WJ; Brand PL
    Acta Paediatr; 2015 Sep; 104(9):916-21. PubMed ID: 26033420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypes of severe asthma among children and adolescents in Brazil: a prospective study.
    de Andrade WC; Lasmar LM; Ricci Cde A; Camargos PA; Cruz ÁA
    BMC Pulm Med; 2015 Apr; 15():36. PubMed ID: 25912047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MODERN APPROACHES TO FRACTIONAL EXHALED NITRIC OXIDE AS A USEFUL BIOMARKER FOR ALLERGIC ASTHMA PHENOTYPING AND MANAGEMENT.
    Mgaloblishvili N; Gotua M
    Georgian Med News; 2017 Dec; (273):51-55. PubMed ID: 29328030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exhaled nitric oxide in the diagnosis and management of childhood asthma.
    Kercsmar C
    Ther Adv Respir Dis; 2010 Apr; 4(2):71-82. PubMed ID: 20215487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exhaled nitric oxide in relation to asthma control: A real-life survey.
    Ricciardolo FL; Sorbello V; Bellezza Fontana R; Schiavetti I; Ciprandi G
    Allergol Immunopathol (Madr); 2016; 44(3):197-205. PubMed ID: 26589339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated fractional exhaled nitric oxide (FeNO) is a clinical indicator of uncontrolled asthma in children receiving inhaled corticosteroids.
    Yin SS; Liu H; Gao X
    Int J Clin Pharmacol Ther; 2017 Jan; 55(1):66-77. PubMed ID: 27443657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of using exhaled NO in asthma diagnosis and management.
    Ludviksdottir D; Diamant Z; Alving K; Bjermer L; Malinovschi A
    Clin Respir J; 2012 Oct; 6(4):193-207. PubMed ID: 22898078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.